-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2121 Understanding the Patient's Experience with Acute Myeloid Leukemia: A Patient Interview Study

Health Services and Outcomes Research – Malignant Diseases
Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Erin L. Tomaszewski1*, Catherine Fickley, PhD, MPH, CPH2*, LeAnne Maddux, MA3*, Robert Krupnick, PhD4*, Erkut Bahceci, MD5, Jean Paty, PhD6* and Floortje van Nooten, MSc7*

1Quintiles, Quintiles, New York
2Patient Centric Advisory Services, Quintiles, Pittsburgh
3Patient Centric Advisory Services, Quintiles, Cambridge
4Advisory Services, Quintiles, Cambridge, MA
5Astellas Pharma US, Inc., Northbrook, IL
6Advisory Services, Quintiles, New York
7Astellas/MA,G, HEOR, Astellas Pharma Europe BV, Leiden, Netherlands

INTRODUCTION: One way to capture the patient reality of living with disease is to talk with patients and listen to them describe their experience.  We sought to understand the patient perspective regarding the signs and symptoms of acute myeloid leukemia (AML) and the impact of these on patients, through direct, qualitative patient interviews. 

METHODS: We conducted individual interviews with patients with AML (median age=48, 37% male) in Japan and the USA following a semi-structured interview guide, containing both open- and closed- ended questions.  These questions aimed to understand the patient’s experience both spontaneously and with specific probing.  Patients were asked to describe their individual experience of living with AML including signs, symptoms, impacts, and the experience during treatment of the disease. 

RESULTS: Forty-one patients were interviewed in the two regions: 23 in US, and 18 in Japan.  The sign, symptom, and impact ‘concepts’ identified were very similar across regions. Forty-nine symptoms were mentioned by US patients; 32 by Japanese patients.  The signs/symptoms reported most frequently and as most bothersome included: fatigue, bruising, weakness, dizziness, shortness of breath, and bleeding (Table 1). Twenty-three unique impacts of signs/symptoms were mentioned in the US and 20 in Japan.  The most frequent and bothersome impacts reported included:  decreased ability to maintain social/familial roles, anxiety, decreased ability to function, depression, fear, remission uncertainty, appetite loss, and low sex drive (Table 1).  These concepts were corroborated by two additional sources:  interviews with clinicians and published literature.

DISCUSSION: The priority concepts expressed by patients were relevant and important to all four AML patient groups in both regions.  This data provides valuable insight into patients’ experiences with AML and helps to select the appropriate patient-reported outcomes for clinical trials. 

Table 1. AML Symptom and Impact Frequencies

 

US Frequency (N=23), n (%)

Japan Frequency (N=18), n (%)

Symptom

Fatigue

22 (95.6)

16 (88.8)

Bruising

18 (78.2)

7 (38.8)

Weakness

18 (78.2)

15 (65.2)

Dizziness

15 (65.2)

12 (52.1)

Shortness of Breath

13 (56.5)

15 (65.2)

Bleeding

12 (52.1)

13 (72.2)

Impact

Decreased ability to maintain social/familial roles

21 (91.3)

13 (72.2)

Anxiety

20 (86.9)

17 (94.4)

Decreased ability to function

20 (86.9)

17 (94.4)

Depression

16 (69.5)

7 (38.8)

Fear

15 (65.2)

12 (52.1)

Remission uncertainty

15 (65.2)

17 (94.4)

Appetite loss

14 (60.8)

13 (72.2)

Low sex drive

11 (47.8)

7 (38.8)

Disclosures: Tomaszewski: Astellas Pharma, Inc.: Consultancy . Fickley: Astellas Pharma, Inc.: Consultancy . Maddux: Astellas Pharma, Inc.: Consultancy . Krupnick: Astellas Pharma, Inc.: Consultancy . Bahceci: Astellas Pharma Global Development: Employment . Paty: Astellas Pharma, Inc.: Consultancy . van Nooten: Astellas: Employment .

*signifies non-member of ASH